The NEST-1 study, which is evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colorectal cancer, both those with Microsatellite Stable (MSS) CRC and Microsatellite Instability High CRC (MSI-High), has demonstrated positive results.
Cancer Research UK and partners on March 31 committed £5.5 million in funding to form a research team tasked with making personalized medicine a reality for people with colorectal cancer. The initiative is designed to unite research expertise and solve unanswered questions about the disease.
